Context: In obesity, adipose tissue (AT) undergoes dynamic remodeling, including an alternation in adipogenesis, AT-resident cell content, angiogenesis, and turnover of extracellular matrix (ECM) components. Studies of AT in humans have been carried out mostly in people with severe metabolic abnormalities, like type 2 diabetes or morbid obesity.
O besity-associated insulin resistance is a major risk factor for type 2 diabetes, atherosclerosis, and cardiovascular disease. Mounting evidence highlights the role of adipose tissue (AT) in systemic inflammation and insulin resistance (1) . In obesity, aberrant AT remodeling is associated with impaired adipogenesis, dysregulation in fatty acid fluxes, disturbed angiogenic remodeling, extracellular matrix (ECM) overproduction, immune cell infiltration, and inflammation (2) .
To maintain proper insulin action, it is essential to maintain adipogenesis (i.e., the ability of AT to recruit new fat cells) because disturbances in this process may lead to an abnormal enlargement of existing adipocytes and to ectopic lipid accumulation. Adipogenesis is controlled by transcription factors, in particular, CCAAT/ enhancer binding protein-a, -b, and peroxisome proliferator activator receptor (PPAR)-g (3) . Impaired adipogenesis and AT dysfunction may manifest with lower expression of these transcription factors (4) .
Pathologically accelerated AT remodeling in obesity is related to ECM remodeling. The degradation of components of the ECM and regulation of AT architecture is mainly mediated by the matrix metalloproteinase (MMP) family and tissue inhibitors of MMP (TIMP), as well as collagens. Pathological remodeling of the ECM that occurs during the expansion of fat mass may reduce the number of AT capillaries (2) . Vascular endothelial growth factor (VEGF) is a key factor involved in AT angiogenesis (5) .
AT inflammation is linked with an activation of signaling pathways associated with cellular kinases, including inhibitor of kB (IkB) kinase (IKK) and c-Jun NH2-terminal kinase (JNK) (6) . IKK is the upstream activating kinase of nuclear factor-kappa-B (NFkB) transcription factors, homo-or hetero-dimers composed of members of the Rel family, including p50 (NFKB1), p52 (NFKB2) or p65 (RELA), resident in the cytoplasm in association with IkB (7) . JNK belongs to the family of serine/threonine mitogen-activated protein kinases (MAPKs) (6) .
In obesity, AT is infiltrated by immune cells, including macrophages, neutrophils, and lymphocytes. Most of the macrophage population in AT of obese subjects consists of proinflammatory M1 macrophages (8) . Some data indicate that AT in the obese state is characterized by increased numbers of cytotoxic T cells and decreased numbers of regulatory T cells (9) .
Immune cells can be distinguished by the expression of cell-surface markers. Macrophages can be identified by CD14 and CD68 expression (10) . M1 macrophages are characterized by CD11c and CD86 expression (11) . CD11b is a marker of macrophages and neutrophils. The general marker for lymphocytes is CD3, whereas cytotoxic T lymphocytes can be identified by CD8 expression and T-helper lymphocytes can be identified by CD4 expression. The typical marker for regulatory T cells is forkhead box P3 (FoxP3) (12) .
Data on the disturbances of adipogenesis, ECM remodeling, and inflammatory reaction in AT stem mainly from experimental studies. Human studies were carried out mostly in people with severe metabolic abnormalities (i.e., type 2 diabetes or morbid obesity). It is relevant to study young, healthy subjects without overt metabolic disturbances to avoid the influence of possible confounding factors. Therefore, the purpose of this study was to investigate subcutaneous AT gene expression of markers of adipogenesis, ECM remodeling, and inflammation in young, healthy subjects with an overweight or obese condition. In particular, we aimed to determine (1) what are the early stages in the development of AT dysfunction and whether disturbances in adipogenesis and/or ECM remodeling are associated with insulin sensitivity early in the course of obesity; (2) what inflammatory pathway(s) in AT are first activated in the course of overweight/obesity; (3) what immune cell markers are altered first in AT; (4) whether peripheral blood mononuclear cells (PBMCs) are already activated in subjects with overweight/uncomplicated obesity; and (5) what are the factors in AT that independently determine an early decrease in insulin action?
Subjects and Methods

Study participants
The study group consisted of 150 healthy volunteers: 117 male subjects and 33 female subjects, 83 of whom were of normal weight [i.e., body mass index (BMI) ,25 kg/m 2 ], 48 were overweight, and 19 were obese. All study participants were nonsmokers, without serious disease or morbid obesity, and not taking any drugs. Subjects were excluded if they had any inflammatory disease within the last 3 months. All subjects had no clinical and laboratory signs of inflammation and had not taken anti-inflammatory drugs within the last 3 months. Anthropometric measurements were performed as previously described (13) . Participants underwent clinical examination and appropriate laboratory tests. Body weight (bw) of the subjects had remained stable for at least 3 months before the study. The study protocol was approved by the local ethics committee of the Medical University of Białystok. A written informed consent was obtained from all volunteers before their participation in the study.
Glucose tolerance and insulin sensitivity
A standard oral glucose tolerance test was performed and all participants had normal glucose tolerance. After 1 week, insulin sensitivity was assessed with the 2-hour euglycemic hyperinsulinemic clamp technique, as previously described (13) and was calculated for bw or fat-free mass (ffm) .
AT biopsies
Before the clamp, AT biopsy was performed under local anesthesia with 1% lidocaine, from the umbilical region with a biopsy needle, as described (14) .
PBMC isolation
PBMCs were isolated from fresh blood using 10 mL of BD Vacutainer CPT Cell Preparation Tube (Becton Dickinson, Franklin Lakes, NJ) with sodium citrate, following the instructions of the manufacturer. All procedures were carried out within 2 hours from blood collection. Pellets were frozen and stored at 280°C before RNA isolation.
Biochemical procedures
Plasma glucose, serum lipids, and insulin were measured as previously described (13, 14) . Serum high-sensitivity C-reactive protein (hsCRP) was measured with particle enhanced immunonephelometry (Dade Behring, Marburg, Germany).
Serum macrophage migration inhibitory factor, monocyte chemoattractant protein 1 (MCP-1), and MMP-9 concentrations were measured with an R&D Systems enzyme-linked immunosorbent assay kit (Minneapolis, MN). Serum interleukin-18 was measured with an MBL enzyme-linked immunosorbent assay kit (Nagoya, Aichi, Japan). Serum adiponectin was measured with a rapid immunoassay kit (Millipore, St. Charles, MO).
Isolation of messenger RNA from AT and PBMCs and determination of gene expression Total RNA was isolated from AT as described (15) . We used QIAshredder spin columns (Qiagen, Austin, TX) to homogenize PBMCs. Total RNA from PBMCs was isolated using the RNeasy Mini Kit (Qiagen).
RNA was treated with the Turbo DNA-free Kit (Ambion, Austin, TX) to remove any trace of DNA. Assessment of RNA quantity and quality were confirmed using an Agilent Technologies 2100 Bioanalyzer and RNA 6000 Nano LabChip kit (Mountain View, CA). RNA purity (A260:A280) was assessed by using a NanoDrop spectrophotometer (NanoDrop 2000; Thermo Fisher Scientific, Wilmington, DE). Reverse transcription was performed using 200 ng of total RNA to synthesize the first strand of complementary DNA, using the QuantiTect Reverse Transcription kit (Qiagen) (16) .
AT messenger RNA (mRNA) expression of markers of adipogenesis, genes of the insulin-signaling pathway, ECM remodeling, inflammatory factors, components of NFkB and MAPK signaling, and markers of immune cells were analyzed with quantitative real-time polymerase chain reaction. In PBMC we analyzed mRNA expression of inflammatory factors, components of NFkB and MAPKs signaling. The samples were quantified with the LightCycler 480 II real-time polymerase chain reaction Instrument (Roche Diagnostics, Mannheim, Germany) using gene-specific primers and probes ( Table 1 ). All samples were run in triplicate and average values were calculated. All results were normalized to the levels of the phosphoglycerate kinase 1 (PGK1) gene because its expression was the most stable in our study group from the fewest possible housekeeping genes tested, and relative quantification was calculated using the DDCt formula cycle threshold.
Statistical analysis
Statistics were performed with the STATISTICA 12.5 program (StatSoft, Krakow, Poland). All data are presented as mean 6 standard deviation. Variables, which did not have a normal distribution, were log transformed before analyses. For data presentation, these variables were antilog transformed again to absolute values. Differences between the groups were analyzed with one-way analysis of variance with BenjaminiHochberg correction for multiple comparisons, followed by a post hoc Tukey test. To assess the effects of sex and age, we used analysis of covariance. The relationship between variables was studied with the Pearson product moment correlation analysis and with multiple regression analysis. The level of significance was accepted as P , 0.05.
Results
Characteristics of the study participants are presented in Table 2 .
Insulin sensitivity, when expressed per kilogram of ffm, was lower in the obese group in comparison with the normal-weight and overweight groups (both P , 0.05), without significant difference between the latter two groups. When expressed per total bw, significant differences in insulin sensitivity among all three groups were observed (all P , 0.05; Table 2 ).
Expression of markers of adipogenesis in AT
In the overweight and obese groups, the expression of CEBPA, CEBPB (only in the obese group), PPARG, and ADIPOQ was significantly lower in comparison with the normal-weight-group (all P , 0.05; Fig. 1 ).
Expression of insulin signaling genes in AT
Overweight and obese subjects had significantly lower expression of IRS1, AKT2, and SLC2A4 (encoding GLUT4). SLC2A4 was also lower in the obese group in comparison with the overweight group. IRS2 was lower in the obese group in comparison with the overweight and normal-weight groups (all P , 0.05; Fig. 1 ).
Expression of markers of ECM remodeling in AT
AT expression of MMP9 and TIMP1 was higher, whereas the expression of VEGFA was lower in the overweight and obese groups in comparison with the normal-weight group. VEGFA was also lower in the obese group in comparison with the normal-weight group (all P , 0.05; Fig. 1 ).
Expression of proinflammatory genes in AT
The expression of CCL2 (encoding MCP-1) and IL18 was higher, whereas the expression of NFKBIA (encoding IkBa) was lower, in the obese group in comparison with the normal-weight and overweight groups. IL18 expression was also higher in the overweight group than in the normal-weight group. We also observed a higher expression of IKBKB (encoding IKKb) in the overweight and obese groups in comparison with the normal-weight group (all P , 0.05). Expression of other inflammatory factors and MAPK pathway genes, including MAPK8 (encoding JNK), did not differ between the study groups (Fig. 2) .
Expression of immune-cell markers in AT
Expression of AT macrophage markers CD14, CD68, ITGAM (encoding CD11b), ITGAX (encoding CD11c), and CD86 was significantly higher in the overweight and obese groups in comparison with the normal-weight group. CD14 was also higher in obese subjects than in 
doi: 10.1210/jc.2017-00597 https://academic.oup.com/jcemoverweight subjects (all P , 0.05; Fig. 3 ). No significant difference in the expression of CD4, CD8A, CD19, CD40, CD3D, and FOXP3 between the groups was observed. The expression of FUT9 and FCGR3A (encoding CD15 and CD16, respectively, which are markers of neutrophils) was not detected. All described differences between the groups were independent of sex and age.
Expression of proinflammatory genes in PBMCs
There were no significant differences in mRNA levels of proinflammatory cytokines in PBMCs between the study groups (data not shown).
Correlations of the estimated parameters with BMI and insulin sensitivity
To study the relationships between the parameters studied, we first used the Pearson product moment correlation analysis. Serum free fatty acid (FFA) levels at 60 and 120 minutes of the clamp, and hsCRP and serum adiponectin levels were related to BMI and insulin sensitivity (Table 3) . Only serum adiponectin level was associated with insulin sensitivity independently of BMI.
We observed inverse relationships between AT expression of CEBPA, CEBPB, PPARG, ADIPOQ, SREBF1, IRS1, IRS2, PIK3CA, AKT2, SLC2A4, VEGFA, NFKBIA, NFKBIL1, and BMI. The expression of MMP9, TIMP1, CCL2, IL18, IKBKB, CD14, CD68, ITGAM, ITGAX, and CD86 positively correlated with BMI (Table 3) . Furthermore, expression of CEBPA, CEBPB, PPARG, ADI-POQ, IRS1, IRS2, PIK3CA, AKT, SLC2A4, VEGFA, and NFKBIL1 positively correlated with fat-free mass insulin sensitivity (M FFM ), and MMP9, CCL2, CD14, CD68, ITGAM, and ITGAX were inversely related to this index (Table 3) . PBMC expression of the estimated genes was not related to BMI and insulin sensitivity (data not shown).
We next used multiple regression analysis to determine the independent determinants of insulin sensitivity. We observed that the relationships of CEBPA (b = 0.28; P = 0.001), ADIPOQ (b = 0.27; P = 0.009), IRS1 (b = 0.21; P = 0.016), IRS2 (b = 0.22; P = 0.009), SLC2A4 (b = 0.43; P , 0.001), and MMP9 (b = 20.34; P = 0.0002) with M FFM were independent of BMI. All the relationships of the discussed parameters with insulin sensitivity were also independent of sex, hsCRP as a marker of systemic inflammation, and of inflammatory and immune cell markers in AT (all P , 0.005). In contrast, correlations of hsCRP, AT proinflammatory genes, and immune-cell marker expression with insulin sensitivity lost their significance after adjustment for BMI as well as after adjustment for the adipogenesis, insulin signaling, and ECM remodeling genes mentioned earlier in Results. 
Discussion
In this study, we observed that young subjects with overweight/moderate obesity, without overt metabolic disturbances, already had altered AT expression of the genes involved in adipogenesis, insulin signaling, AT remodeling, angiogenesis, inflammation, and reflecting immune-cell infiltration. We did not find any differences in PBMC inflammatory gene expression between the studied groups. Furthermore, we found that only genes Figure 2 . Difference in mRNA expression of proinflammatory markers in AT between normal-weight (n = 83), overweight (n = 48), and obese (n = 19) subjects. *P , 0.05 vs. normal-weight subjects. https://academic.oup.com/jcemassociated with ECM remodeling, adipogenesis, and insulin signaling, but not inflammation, were related to insulin sensitivity independently of BMI.
We assessed the adipogenic potential of AT and observed that AT expression of CEBPA, CEBPB, PPARG, and ADIPOQ was decreased in the overweight/obese groups. Acosta et al. (17) observed that the expression of CEBPA and PPARG correlated negatively with fat cell size. In the study of obese subjects, CEBPA expression was negatively related to BMI (15) . Additionally, decreased adipogenic marker expression in obese subjects (18) and in first-degree relatives of patients with type 2 diabetes (19) was observed. In the current study, the expression of insulin signaling genes and SLC2A4, which may also be markers of adipogenesis, was decreased as well.
We observed an increased AT expression of MMP9, a key mediator of ECM remodeling, together with an increased expression of TIMP1 in overweight/obese subjects. It was observed that subcutaneous AT MMP9 was positively related to BMI (20) . ECM remodeling is important for adipocyte differentiation and inhibition of MMPs impaired AT development in mice (21) . TIMP-1 was demonstrated to inhibit adipogenesis, which led to enlarged adipocytes in the state of overnutrition (16).
Pathological AT ECM remodeling coexists with an impaired angiogenesis, which is in line with the decreased VEGFA expression in the overweight/obese group in our study. Lower AT VEGFA expression was also demonstrated in subjects with insulin resistance and increased BMI (22) . In contrast, in another study (23) , increased subcutaneous AT VEGFA expression in insulin-resistant subjects compared with insulin-sensitive subjects was reported; however, mean BMI was.40 kg/m 2 and did not significantly differ between the groups. AT VEGF overexpression protected against high-fat-diet-induced obesity in mice (24) . Together, our data suggest complex AT insufficiency, which is already present in young subjects with an overweight/ obese condition without overt metabolic disturbances. Another important condition associated with obesity is AT inflammation. We assessed the most important inflammatory pathways in AT at the transcriptional level and found the alterations in the genes of NFkB signaling but not MAPK/JNK signaling or toll-like receptors in overweight/obesity. The change observed in the expression of NFKBIA (encoding IkBa) is particularly important because it was demonstrated that the measurement of IkBa mRNA is a sensitive and powerful method to quantify the transcriptional power of NFkB and can be used for clinical evaluation of NFkB status (25) . The evidence about the initial alterations in inflammatory process in obesity is conflicting and the underlying mechanism remains unclear. Zamboni et al. (26) showed that AT mRNA expression of IkBa was inversely related to waist circumference and AT adiponectin expression. Studies have demonstrated the NFkB pathway is the major factor responsible for AT inflammation in obesity and associated conditions (27, 28) . On the other hand, some studies indicate an important role of JNK signaling in obesity-related inflammation (6) . Our data indicate that the changes in NFkB pathway are characteristic for uncomplicated overweight/obese cases. We cannot exclude the possibility that in more pronounced metabolic disturbances or other AT depots, one may observe alterations in MAPK/JNK pathways. In obesity, there could be insufficient angiogenesis leading to AT hypoxia and inflammation, and, in turn, inflammatory factors may stimulate extended angiogenesis in AT. The expression of VEGFA, a marker of angiogenesis, and inflammatory parameters were related to insulin sensitivity in an opposite manner and were not related to each other. In our opinion, these data do not indicate that extended angiogenesis/vasculature is present in the early phase of AT inflammation.
We also found increased AT macrophage-marker expression in overweight/obesity-both general markers and those characteristic for proinflammatory macrophages. We did not observe differences in other immune-cell markers studied. Increased macrophage-marker expression in obesity was also demonstrated in other studies (29, 30) . Kang et al. (31) did not observe an increase in macrophage markers in obesity; however, they studied visceral AT. AT macrophage infiltration in obesity is well established; however, the initiating factor remains unclear. Zeyda et al. (32) reported an increased AT expression of markers of T cells, both unfavorable and protective, in morbidly obese patients in comparison with nonobese subjects. T-cell markers were positively related to the macrophage marker CD68 within the obese group (32). Travers et al. (33) demonstrated an increase in CD4 and FOXP3 expression with increasing adiposity, together with an increase in CD68. They suggested the presence of potential compensatory mechanisms to counteract AT inflammation, possibly through an increase in T-regulatory cells (33) . We did not find any difference in T-cell marker expression. However, in contrast to Zeyda et al. (32), we have not examined subjects with morbid obesity. In comparison with Travers et al. (33) , our study group was approximately 20 years younger. Thus, our data indicate that macrophages are the first immune cells recruited to AT. We also found increased expression of mRNA encoding MCP-1 in AT of obese subjects-chemokines mainly associated with AT macrophage infiltration. Interestingly, chemokine expression and macrophage infiltration in inflamed AT are mainly mediated by the NFkB pathway (33) . One may hypothesize that altered ECM remodeling and impaired adipogenesis may lead to macrophage infiltration. However, the causality between these processes cannot be established on the basis of our results.
We did not find any differences in inflammatory gene expression in PBMCs. Ghanim et al. (34) reported that PBMC in obesity exhibited an increased NFkB activity and transcription of its target genes. The mean BMI in the obese group in their study was approximately 37 kg/m 2 (34). In another report, genes involved in NFkB activation in PBMC decreased after weight loss (35) . However, the study group included women with prediabetes and metabolic syndrome. In contrast, Travers et al. (33) did not observe any relation of PBMC activation with adiposity, which may support our data. Our study might suggest that in obesity inflammation begins in AT, where macrophages acquire their proinflammatory phenotype.
Another important purpose of our study was to identify genes in AT that are related to insulin sensitivity. Most of the genes differing between the study groups were also related to insulin sensitivity. However, only six genes were related to insulin sensitivity independently of BMI: CEBPA, ADIPOQ, MMP9, IRS1, IRS2, and SLC2A4. Interestingly, correlations between insulin sensitivity and inflammatory parameters, including hsCRP as a marker of systemic inflammation, lost significance after adjustment for BMI or adipogenic gene expression. This indicates that in early uncomplicated obesity, AT inflammation is associated with adiposity itself and not with insulin resistance. Travers et al. reported correlation between the percentage of macrophages in the stromal vascular fraction and homeostatic model assessment of insulin resistance; however, adjustment for BMI was not reported (33). Acosta et al. (17) showed no difference in subcutaneous AT immune-cell population frequencies between nonobese healthy subjects and those with type 2 diabetes. Despite many studies, early stages of AT inflammation in obesity remain unclear. Taken together, these data suggest that altered adipogenesis and ECM remodeling, not inflammation, are the primary processes in subcutaneous AT associated with whole-body insulin sensitivity. It is important to note that skeletal muscle is the most important tissue responsible for insulin-stimulated glucose uptake during the clamp. It is supposed that AT influences whole-body insulin sensitivity through the release of FFAs and adipocytokines. Fasting FFA levels were not different between the groups. FFA levels during the clamp were higher in overweight/obese subjects; however, they were not independent determinants of insulin sensitivity. Adiponectin could have important role. The results of multiple regression analysis do not support the idea that inflammatory factors are the early mediators of insulin resistance. One should rather hypothesize that alterations in adipogenesis and ECM remodeling together lead to an impairment in adipocyte function and possibly to ectopic lipid accumulation.
Our study provides an insight into AT gene expression profile in early overweight/moderate obesity. A similar approach was taken by Travers et al. (33) and Kang et al. (31) . Both studies included subjects who were approximately 20 years older than the subjects in our study group, and both were focused on inflammatory factors, without assessing ECM remodeling and adipogenic markers. Kursawe et al. (36) examined subcutaneous AT gene expression in adolescents; however, they compared obese subjects on the basis of magnetic resonance imaging-derived measurements of abdominal AT, and both groups had mean BMI .37 kg/m 2 . Thus, we provide information about the early determinants of insulin resistance in obesity, independent of BMI, sex, hsCRP level, and inflammatory-and immune-cell markers in AT. Our findings may have potential implications for management strategies in the treatment of metabolic complications of obesity. Potential limitations of our study include lack of validation of results at the protein level, which was impossible because of limited tissue availability, as well as lack of controlling for the possible effect of AT biopsy on the measurement of insulin action, which may be different in obese and normal-weight subjects.
In conclusion, overweight/obesity is associated with altered expression of genes of ECM remodeling, adipogenesis, insulin signaling, and inflammation. NFkB seems to be the earliest inflammatory pathway altered at the transcriptional level in AT. Macrophages seem to be the first immune cells to infiltrate AT. ECM remodeling and adipogenesis are the initial processes in AT associated with insulin sensitivity.
